Latest News and Press Releases

PharmAla files Q2 quarterly financials with increased customer deposits.

PharmAla is positioned to supply the US market with MDMA, and is advancing its next-generation patented safer MDMA product for human dosing this year.

PharmAla provides an update on Cortexa, its Australian joint venture with Vitura Health.

Pharmala announces a newly signed contract to supply a clinical trial, and the fulfillment of a previously announced trial.

PharmAla to receive clinical trial data from harvard-affiliated hospital in exchange for a drug donation

PharmAla to supply University of Amsterdam with LaNeo MDMA for a clinical trial, generating new stability data for blister packs in the process

PharmAla announces the resignation of Dr. Malik Slassi and the appointment of Mr Lennie Ryer to its board.

Anonymous survey with optional confidential interviews will document how practitioners facilitate MDMA-assisted couples therapyFindings to inform ethical guidelines, future clinical trial protocols,...

PharmAla inks contract with Ostfold Hospital Trust in Oslo to supply clinical trial in exchange for both cash and a data license

PharmAla files its audited year end and unaudited Q1 financials.